ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
In breaking news, clinical-stage biotechnology company ImmunityBio, Inc. (NASDAQ: IBRX) has announced acceptance by the FDA review of…
Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement
Clinical-stage pharmaceutical company Brickell Biotech, Inc. (Nasdaq: BBI) announced that the company has received formal notice from The…
Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…